Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-12
2011-07-12
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07977321
ABSTRACT:
The present application provides polynucleotides, compositions thereof and methods of treating feline herpes virus infections. In certain embodiments, the polynucleotides and compositions thereof can be used to reduce replication of feline herpes simplex virus 1 (FHV-1) in vivo and/or in vitro.
REFERENCES:
patent: 2004/0259247 (2004-12-01), Tuschl et al.
Barton, G. and Medzhitov, R., “Retroviral delivery of small interfering RNA into primary cells”,Proc Natl Aced Sci, Nov. 12, 2002, pp. 14943-14945, vol. 99, No. 23.
Bhuyan, P. et al., “Short Interfering RNA-Mediated Inhibition of Herpes Simplex Virus Type 1 Gene Expression and Function during Infection of Human Keratinocytes”,Journal of Virology, Oct. 2004, pp. 10276-10281, vol. 78, No. 19, American Society for Microbiology.
Bitko, V. et al., “Inhibition of respiratory viruses by nasally administered siRNA”,Nature Medicine, Jan. 2005, pp. 50-55, vol. 11, No. 1, Nature Publishing Group.
Devroe, E. and Silver, P., “Retrovirus-delivered siRNA”,BMC Biotechnology, 2002, pp. 1-5, vol. 2, No. 15.
Fattal, E. et al., “Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides”,Journal of Controlled Release, 1998, pp. 137-143, vol. 53, Elsevier Science B.V.
Kim, D. and Rossi, J., “Strategies for silencing human disease using RNA interference”,Nature Reviews Genetics, Mar. 2007, pp. 173-184, vol. 8, Nature Publishing Group.
Lambert, G. et al., “Nanoparticulate systems for the delivery of antisense oligonucleotides”,Advanced Drug Delivery Reviews, 2001, pp. 99-112, vol. 47, Elsevier Science B.V.
Li, B. et al., “Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque”,Nature Medicine, Sep. 2005, pp. 944-951, vol. 11, No. 9, Nature Publishing Group.
Morris, M. et al., “Translocating peptides and proteins and their use for gene delivery”,Current Opinion in Biotechnology, 2000, pp. 461-466, vol. 11, Elsevier Science Ltd.
Nasisse, M. et al., “Detection of feline herpesvirus 1 DNA in corneas of cats with eosinophilic keratitis or corneal sequestration”,Am J Vet Res, Jul. 1998, pp. 856-858, vol. 59, No. 7.
Nasisse, M. et al., “Experimental Ocular Herpesvirus Infection in the Cat”,Investigative Ophthalmology&Visual Science, Aug. 1989, pp. 1758-1768, vol. 30, No. 8, Association for Research in Vision and Ophthalmology.
Palliser, D. et al., “An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection”,Nature, Jan. 5, 2006, pp. 89-94, vol. 439, Nature Publishing Group.
Paul, C. et al., “Effective expression of small interfering RNA in human cells”,Nature Biotechnology, May 2002, pp. 505-508, vol. 29, Nature Publishing Group.
Shuey, D. et al., “RNAi: gene-silencing in therapeutic intervention”,Drug Discovery Today, Oct. 2002, pp. 1040-1046, vol. 7, No. 20, Elsevier Science Ltd.
Spagnou, S. et al., “Lipidic Carriers of siRNA: Differences in the Formulation, Cellular Uptake, and Delivery with Plasmid DNA”,Biochemistry, 2004, pp. 13348-13356, vol. 43, No. 42, American Chemical Society.
Sui, G. et al., “A DNA vector-based RNAi technology to suppress gene expression in mammalian cells”,Proc Natl Aced Sci, Apr. 16, 2002, pp. 5515-5520, vol. 99, No. 8.
GenBank Accession No. AF079125.1, Mar. 16, 2000, pp. 1-2.
GenBank Accession No. AJ224971, Mar. 11, 1998, pp. 1-4.
GenBank Accession No. D30767.1, Feb. 17, 2007, pp. 1-3.
Wilkes, R. and Kania, S., “Can an ancient defense mechanism against viral infections in yeast, plants, and mammals help prevent or cure cate flu?”Winn News, Winter 2005, pp. 1-4.
Wilkes, R. and Kania, S., “RNA interference of the glycoprotein-D and DNA polymerase genes of feline herpesvirus by synthetic siRNAs”,The Winn Feline Foundation for the Health and Well-Being of All Cats, 2005 Grant Awards, George and Phyllis Miller Trust.
Wilkes, R. et al. “Evaluation of the effects of small interfering RNAs on in vitro replication of feline herepsvirus-1,”AJVR, Jun. 2010, pp. 655-663, vol. 71, No. 6.
Wilkes, R. P. et al. “Use of interfering RNAs targeted against feline herpesvirus 1 glycoprotein D for inhibition of feline herpesvirus 1 infection of feline kidney cells”AJVR, Aug. 2009, pp. 1018-1025, vol. 70, No. 98.
Kania Stephen A.
Wilkes Rebecca P.
McGarry Sean R
Saliwanchik Lloyd & Eisenschenk
University of Tennessee Research Foundation
LandOfFree
Small interfering RNAs targeting feline herpes virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small interfering RNAs targeting feline herpes virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small interfering RNAs targeting feline herpes virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635731